An Experience using Venetoclax and Azacitidine in a Treatment-Naïve
Adolescent with Acute Myeloid Leukemia Secondary to Myelodysplastic
Syndrome
Abstract
Refractory/relapsed acute myeloid leukemia is an advanced hematological
malignancy with a poor prognosis in pediatric. The therapeutic options
are limited and has been slow development of therapies for this age
group. A combination of Venetoclax and Azacitidine therapy in newly
diagnosed elderly patients with acute myeloid leukemia and
refractory/relapsed disease has achieved impressive results. Whether
similar results can be attained in pediatric patients is unknown. We
present a case of adolescent girl with acute myeloid leukemia secondary
to myelodysplastic syndrome, who was deemed unfit to undergo
conventional chemotherapy and, was treated instead with the Venetoclax
and Azacitidine.